Tech Company Financing Transactions
Regado Biosciences Funding Round
On 12/20/2012, Regado Biosciences raised $51 million in Series E funding from RusnanoMedInvest, Aurora Funds and Baxter Ventures.
Transaction Overview
Company Name
Announced On
12/20/2012
Transaction Type
Venture Equity
Amount
$51,000,000
Round
Series E
Investors
RusnanoMedInvest (Lead Investor)
Domain Associates (Dennis Podlesak)
Proceeds Purpose
Proceeds from the financing will support Regado's REGULATE -- PCI Phase 3 clinical study of REG1. This is the company's lead development program for REG1 in arterial thrombosis and is being developed for use in percutaneous coronary intervention (PCI) in the acute coronary syndrome (ACS) population. Regado is also pursuing an additional parallel development program for REG1 for use in Open Heart Surgery. While the vast majority of the funding will be used for the Phase 3 development of REG1 for PCI, some funding will be used to advance other development programs in the Regado pipeline such as REG1 for TAVI (transaortic valve implantation) and REG3 in diabetic vasculopathy.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
701 Gateway Blvd. 300
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Regado (NASDAQ: RGDO) is a spin-out of the Department of Surgery at Duke University Medical Center. Regado's technology enables the rational design of drug-antidote pairs against any target accessible to the bloodstream.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Laurent Fischer
Chief Financial Officer
Christopher Peetz
Chief Medical Officer
Eric Lefebvre
Chief Operating Officer
Helen Jenkins
Browse more venture capital transactions:
Prev: 12/20/2012: VeraLight venture capital transaction
Next: 12/20/2012: Signifyd venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs